(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 5.22% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Haemonetics's revenue in 2026 is $1,352,013,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2027 to be $64,423,824,216, with the lowest HAE revenue forecast at $61,921,486,411, and the highest HAE revenue forecast at $68,200,079,449. On average, 12 Wall Street analysts forecast HAE's revenue for 2028 to be $67,745,108,939, with the lowest HAE revenue forecast at $64,332,830,114, and the highest HAE revenue forecast at $72,249,316,988.
In 2029, HAE is forecast to generate $71,885,340,580 in revenue, with the lowest revenue forecast at $68,154,582,398 and the highest revenue forecast at $76,298,554,527.